`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`
`
`
`
`
`
`08.01.2022
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain
`Rights for the Private Label Version of Lumify in the US
` |
`
`Dr. Reddyʼs Laboratories, along with its subsidiaries, announced it has entered into a licensing
`agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slaybackʼs
`Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify in
`United States. Lumify (Bausch + Lomb) is an over-the-counter (OTC) eye drop that can be used
`to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr.
`Reddyʼs exclusive rights to the product outside the US.
`
`Slayback Pharma is the first company to file an abbreviated new drug application for the
`private label equivalent for Lumify with the FDA under Paragraph IV certification. The
`abbreviated NDA is currently under FDA review and covers Brimonidine Tartrate Ophthalmic
`Solution 0.025% in 2.5 ml and 7.5 ml fill volumes.
`
`“We are pleased to license this important OTC ophthalmic product for the U.S. market,” Marc
`Kikuchi, Chief Executive O icer, North America Generics, Dr. Reddyʼs, said in a company news
`release. “This product complements Dr. Reddyʼs growing OTC product portfolio in the eye care
`category that includes the private label versions of Pataday Once Daily Relief and
`Pataday Twice Daily Relief.”
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 1/4
`
`Eye Therapies Exhibit 2097, 1 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`Menu
`Search
`Share
`Copy Link
`
`
`8/16/22, 11:24 AM
`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`08.15.2022
`Opthea Announces Financing Deals for OPT-302 in Wet AMD
`Eyewire News
`
`How to Diagnose and Treat Nocturnal Lagophthalmos
`ack e Ga ch, OD, AAO, and es e O De , OD, AAO
`Eyetube
`
`08.08.2022
`Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for
`Up to $65 Million
`Eyewire News
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 2/4
`
`Eye Therapies Exhibit 2097, 2 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`More in Business
`Next Article
`
`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`8/16/22, 11:24 AM
`07.29.2022
`Lenstec Receives FDA Approval for the SBL-3 Multifocal IOL
` |
`
`Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL
`(Segmented Bifocal Lens) is a next generation asymmetric multifocal refractive IOL
`that provides patients with near, intermediate and distance vision. Its patented design allows
`for improved contrast sensitivity and minimized halo and glare (dysphotopsias) commonly
`associated with other traditional 'concentric ring' multifocal IOLs, according to a company
`news release.
`
`The segmented optic design is the first of its kind in the US. Lenstec's patented four point
`fixation and design allow surgeons confidence in the IOLs e ective lens position within the
`capsule. Its availability in 0.25 diopter power increments, along with tolerances (+/- 0.11
`diopters from labeled power), assists surgeons in achieving the best refractive outcomes
`possible.
`
`"SBL 3 lens patients reported high quality distance and near vision, without the headache of
`severe dysphotopsia issues, and we had no complaints with computer vision," James Loden,
`MD, a principal investigator in the FDA trial, said in the news release.
`
`Sebastian Heersink, MD, another FDA trial principal investigator, stated, "In my own experience
`with the SBL-3, I have been very impressed with the quality and range of functional vision
`patients obtained, as well as their overall happiness. It performs well in low lighting and
`patients report excellent night driving. It's a great lens that I wouldn't hesitate to have
`implanted in my own eyes."
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 3/4
`
`Eye Therapies Exhibit 2097, 3 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
` Share
` Copy Link
`
`
`8/16/22, 11:24 AM
`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`08.16.2022
`First SBL-3 ClearView Multifocal Intraocular Lens Implanted in US
`Eyewire News
`
`08.16.2022
`Sight Sciences Announces Long Term Safety and E ectiveness Data of Standalone Use of the Omni Surgical
`System in Patients with Open Angle Glaucoma
`Eyewire News
`
`0 16 2022
`First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment System
`Eyewire News
`
`ABOUT EYEWIRE+
`Eyewire+ keeps readers updated with the latest in the ophthalmic field, featuring breaking news from press
`eleases, medical journals, vision publications, videos, and other news sources
`
`
`
`GET EMAIL UPDATES
`
`FOLLOW US
`
`
`
`
`
`
`
`Advertising
`
`Privacy Policy
`
`© 2022 Bryn Mawr Commun cat ons LLC.
`A R ghts Reserved • Pr vacy Po cy
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 4/4
`
`Eye Therapies Exhibit 2097, 4 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`More in Cataract
`Eyewire News
`EyewireTV
`Topics
`Events
`Send a Tip
`Contact
`About
`BMC Vision
`